Back

Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55/YY1/sST2 signaling axis

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in basic science 1 Gene Therapy, Cell Therapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Miss Miriam Ruiz Ballester

Foundation for Health Research and Training, Murcia (Spain)

5 More presentations in this session

Presentation thumbnail
SET7 lysine methyltransferase mediates NLRP3 inflammasome priming and activation in atherosclerotic apolipoprotein E knockout mice
Doctor A. Manea (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
Benefit of treatment with Cemtirestat on connexin 43 in the heart and brown adipose tissue of male Zucker diabetic fatty rats.
Doctor T. Egan Benova (Bratislava, SK)
Abstract Slides Video
Presentation thumbnail
SET7 lysine methyltransferase mediates the up-regulation of vascular NADPH oxidase expression in diabetic mice
Doctor S. Manea (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
HFWM: hidden cardiotoxicity of tyrosine kinase inhibitors is associated with a distinct expression pattern of long non-coding RNAs
Mr R. Bernasconi (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Profiling of mirnas involved in sympatho-excitation as a therapeutic strategy to combat atrial fibrillation
Professor I. Murtaza (Islamabad, PK)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in basic science 1

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
The role of TAK1 inhibition in doxorubicin-induced cardiotoxicity: an in vitro study
thumbnail
Congress Presentation
MicroRNA signatures and machine learning models for predicting cardiotoxicity in HER2 positive breast cancer patients
thumbnail
Congress Presentation
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources